-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On October 21, the CDE official website showed that the clinical trial application of Hengrui SHR8554 combined with SHR0410 for the treatment of postoperative acute moderate to severe pain was approved by the China Food and Drug Administration
Postoperative pain is caused by the trauma of the operation itself, which can cause acute pain caused by damage to the skin, nerves, blood vessels, and internal organs.
SHR8554 injection is a small molecule drug targeting the μ opioid receptor (MOR), which can activate the MOR receptor and is suitable for the treatment of pain
Note: The original text has been deleted